Tech Company Financing Transactions
Lyra Therapeutics Funding Round
Lyra Therapeutics, operating out of Watertown, received $29.5 million in funding from Perceptive Advisors, ArrowMark Partners and Intersouth Partners.
Transaction Overview
Company Name
Announced On
9/27/2018
Transaction Type
Venture Equity
Amount
$29,500,000
Round
Series B
Investors
Perceptive Advisors (Lead Investor) (Michael Altman)
Proceeds Purpose
Proceeds from the financing will be used to advance the company's lead product candidate, LYR-210, into a Phase 2 clinical study for chronic rhinosinusitis, as well as applying Lyra's proprietary transmucosal platform for other ENT diseases.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
480 Arsenal Way
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Website
Email Address
Overview
Lyra Therapeutics (Nasdaq: LYRA) is a clinical-stage company developing medicines precisely designed to target ear, nose and throat (ENT) diseases. Our goal is to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Maria Palasis
Chief Financial Officer
Donald Elsey
VP - Bus. Development
Corinne Noyes
VP - Operations
Laura Edgerly-Pflug
VP - R & D
Robert Richard
VP - Regulatory Affairs
Vineeta Belanger
Browse more venture capital transactions:
Prev: 9/27/2018: Maven venture capital transaction
Next: 9/27/2018: iSpot.tv venture capital transaction
Share this article
News on VC Transactions
We record all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs